Rocket Pharmaceuticals Operating Expenses Growth & History (RCKT)
Rocket Pharmaceuticals's operating expenses was $231.7M for fiscal 2025.
View full Rocket Pharmaceuticals company overviewRocket Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $231.7M | −$41.5M | −15.17% |
| 2024 | 2024-12-31 | $273.2M | $13.5M | +5.22% |
| 2023 | 2023-12-31 | $259.7M | $35.3M | +15.74% |
| 2022 | 2022-12-31 | $224.3M | $57.1M | +34.14% |
| 2021 | 2021-12-31 | $167.2M | $32.9M | +24.53% |
| 2020 | 2020-12-31 | $134.3M | $58.2M | +76.36% |
| 2019 | 2019-12-31 | $76.2M | $5.0M | +7.02% |
| 2018 | 2018-12-31 | $71.2M | $51.4M | +259.88% |
| 2017 | 2017-12-31 | $19.8M | $12.2M | +161.05% |
| 2016 | 2016-12-31 | $7.6M | — | — |
Rocket Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.9M | −$24.2M | −34.05% |
| Q1 2026 | 2026-03-31 | $48.5M | −$15.9M | −24.66% |
| Q4 2025 | 2025-12-31 | $44.0M | −$18.7M | −29.88% |
| Q3 2025 | 2025-09-30 | $52.2M | −$17.2M | −24.74% |
| Q2 2025 | 2025-06-30 | $71.1M | −$2.6M | −3.48% |
| Q1 2025 | 2025-03-31 | $64.4M | −$3.0M | −4.43% |
| Q4 2024 | 2024-12-31 | $62.7M | −$585,000 | −0.92% |
| Q3 2024 | 2024-09-30 | $69.4M | $4.0M | +6.11% |
| Q2 2024 | 2024-06-30 | $73.7M | $5.0M | +7.21% |
| Q1 2024 | 2024-03-31 | $67.4M | $5.2M | +8.33% |
| Q4 2023 | 2023-12-31 | $63.3M | −$5.8M | −8.40% |
| Q3 2023 | 2023-09-30 | $65.4M | $6.9M | +11.87% |
| Q2 2023 | 2023-06-30 | $68.8M | $14.5M | +26.83% |
| Q1 2023 | 2023-03-31 | $62.2M | $19.6M | +46.12% |
| Q4 2022 | 2022-12-31 | $69.1M | $24.7M | +55.83% |
| Q3 2022 | 2022-09-30 | $58.5M | $8.8M | +17.81% |
| Q2 2022 | 2022-06-30 | $54.2M | $20.2M | +59.22% |
| Q1 2022 | 2022-03-31 | $42.6M | $3.3M | +8.52% |
| Q4 2021 | 2021-12-31 | $44.3M | −$14.9M | −25.16% |
| Q3 2021 | 2021-09-30 | $49.6M | $22.3M | +81.28% |
| Q2 2021 | 2021-06-30 | $34.0M | $10.5M | +44.52% |
| Q1 2021 | 2021-03-31 | $39.2M | $15.1M | +62.61% |
| Q4 2020 | 2020-12-31 | $59.2M | $39.6M | +201.48% |
| Q3 2020 | 2020-09-30 | $27.4M | $8.2M | +42.90% |
| Q2 2020 | 2020-06-30 | $23.6M | $5.2M | +28.09% |
| Q1 2020 | 2020-03-31 | $24.1M | $5.2M | +27.32% |
| Q4 2019 | 2019-12-31 | $19.6M | −$6.9M | −25.98% |
| Q3 2019 | 2019-09-30 | $19.2M | $3.8M | +24.99% |
| Q2 2019 | 2019-06-30 | $18.4M | $3.5M | +23.67% |
| Q1 2019 | 2019-03-31 | $18.9M | $4.5M | +31.52% |
| Q4 2018 | 2018-12-31 | $26.5M | $19.9M | +298.83% |
| Q3 2018 | 2018-09-30 | $15.3M | $8.6M | +128.00% |
| Q2 2018 | 2018-06-30 | $14.9M | $11.4M | +322.38% |
| Q1 2018 | 2018-03-31 | $14.4M | $11.5M | +401.92% |
| Q4 2017 | 2017-12-31 | $6.7M | — | — |
| Q3 2017 | 2017-09-30 | $6.7M | — | — |
| Q2 2017 | 2017-06-30 | $3.5M | — | — |
| Q1 2017 | 2017-03-31 | $2.9M | — | — |
Rocket Pharmaceuticals operating expenses trends
Over the last five fiscal years, Rocket Pharmaceuticals's operating expenses increased from $134.3M to $231.7M, a change of $97.4M. The latest reported quarter, Q2 2026, shows $46.9M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rocket Pharmaceuticals source filings ↗